Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation

Abstract

Atrial fibrillation (AF) ablation is an established therapy for symptomatic AF. As a non-pharmacological therapy for AF that in ∼60–70% of patients provides a durable reduction in AF recurrence risk, there exists hope that AF-related co-morbidities may be reduced. Large observational trials have shown that AF ablation is associated with lower rates of stroke, dementia, heart failure, and mortality.1,2

Read More

Topics: 

Citation
Eur Heart J. 31 January, 2019. Epub ahead of print.